Skip to main content
. Author manuscript; available in PMC: 2013 Apr 19.
Published in final edited form as: Mol Immunol. 2012 Aug 18;53(0):132–139. doi: 10.1016/j.molimm.2012.07.012

Fig. 1.

Fig. 1

E23A inhibits complement activity both in vitro and in vivo. (A) Human O serum was incubated with increasing concentrations of E23A in DMSO and then added to human AB erythrocytes. Values are the means of three independent experiments. Error bars represent the SEM. (B) NHS was incubated with increasing concentrations of E23A in DMSO and then added to mannan coated plates. C3 deposition was measured by ELISA. (C) Three male Wistar rats received IP injection of either 20 mg E23A or vehicle control (DMSO). Blood was collected before and one hour after injection, from which serum was isolated and tested in hemolytic assays with erythrocytes. Values are the means of three independent experiments. Error bars represent the SEM.